Literature DB >> 20661054

Management of pregnancy after stillbirth.

Uma M Reddy1.   

Abstract

It is difficult for clinicians to counsel, evaluate, and manage subsequent pregnancies after stillbirth as little is known about pregnancy outcome after a stillbirth. In a significant number of cases, either the evaluation was incomplete or the prior stillbirth remains unexplained despite a complete work-up. In addition, there are important psychological and emotional issues when dealing with a pregnancy resulting in a stillbirth. The overall recurrence risk for stillbirth is increased 2 to 10 folds in the next pregnancy, depending on the circumstances. Understanding the circumstances of the previous stillbirth is important for counseling about stillbirth recurrence risk. Categorization of the cause of the previous stillbirth will allow better estimation of individual recurrence risk of the condition that is associated with stillbirth and help guide management.

Mesh:

Substances:

Year:  2010        PMID: 20661054     DOI: 10.1097/GRF.0b013e3181eba25e

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  3 in total

Review 1.  Factor V Leiden 1691G > A mutation and the risk of recurrent pregnancy loss (RPL): systematic review and meta-analysis.

Authors:  Mohammad Masoud Eslami; Majid Khalili; Mina Soufizomorrod; Saeid Abroun; Bahman Razi
Journal:  Thromb J       Date:  2020-06-24

2.  Stillbirth and neonatal mortality in a subsequent pregnancy following stillbirth: a population-based cohort study.

Authors:  Janna W Nijkamp; Anita C J Ravelli; Henk Groen; Jan Jaap H M Erwich; Ben Willem J Mol
Journal:  BMC Pregnancy Childbirth       Date:  2022-01-04       Impact factor: 3.007

Review 3.  A structured review and exploration of the healthcare costs associated with stillbirth and a subsequent pregnancy in England and Wales.

Authors:  Hema Mistry; Alexander E P Heazell; Oluwaseyi Vincent; Tracy Roberts
Journal:  BMC Pregnancy Childbirth       Date:  2013-12-17       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.